Heart rate in ischemic heart disease. The innovation of ivabradine: More than pure heart rate reduction

Advances in Therapy

Volumn 27, Issue 4, 2010, Pages 202-210

  Rosano, Giuseppe M C ^a,b   Vitale, Cristiana ^a   Volterrani, Maurizio ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b San Raffaele Sulmona   (Italy)

Author keywords

Acute myocardial infarction; Coronary artery disease; Heart rate; Myocardial ischemia

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IVABRADINE; METOPROLOL; NICORANDIL; NITRATE; PLACEBO; PROPRANOLOL; TIMOLOL; TRIMETAZIDINE;

ACUTE HEART INFARCTION; ANGINA PECTORIS; BRADYCARDIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; EXERCISE TOLERANCE; HEART DEPOLARIZATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; REVIEW; SINUS RHYTHM; STABLE ANGINA PECTORIS; VISUAL DISORDER;

ADRENERGIC BETA-ANTAGONISTS; BENZAZEPINES; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; HEART RATE; HUMANS; MYOCARDIAL ISCHEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77953021351     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0030-9     Document Type: Review

References (56)

1. Palatini P, Thijs L, Staessen JA, et al. Predictive power of clinical and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med. 2002;162:2313- 2321.
2. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26:967-974.
3. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005;352:1951-1958. (Pubitemid 40638365)
4. Palatini P, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens. 2004;26:637-644.
5. Palatini P, Benetos A, Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs. 2006;66:133-144.
6. Fox KM. Exercise heart rate/ST segment relation. Perfect predictor of coronary disease. Br Heart J. 1982;48:309-310.
7. Perret-Guillaume C, Joly L, Benetos A. Heart rate as a risk factor for cardiovascular disease. Prog Cardiovasc Dis. 2009;52:6-10.
8. Beddhu S, Nigwekar SU, Ma X, Greene T. Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease. Nephrol Dial Transplant. 2009;24:2482-2488.
9. Longenecker JC, Zubaid M, Johny KV, et al. Association of low heart rate variability with atherosclerotic cardiovascular disease in hemodialysis patients. Med Princ Pract. 2009;18:85-92.
10. Reil JC, Böhm M. The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol. 2007;96:585-592.
11. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372:817-821.
12. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. BEAUTIFUL investigators. Ivabradine for patients with stable coronary artery disease and leftventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807-816.
13. Ferrari R, Ford I, Fox K, Steg PG, Tendera M. BEAUTIFUL study group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology. 2008;110:271-282.
14. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986;57:43F-49F.
15. Gundersen T, Grottum P, Pedersen T, Kjekshus JK. Effect of timolol on mortality and reinfarction after acute myocardial infarction: prognostic importance of heart rate at rest. Am J Cardiol. 1986;58:20-24.
16. Boissel JP, Leizorovicz A, Picolet H, Peyrieux JC. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol. 1990;66:251-260. (Pubitemid 20235745)
17. Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40:1589-1595.
18. Heller DA, Ahern FM, Kozak M. Changes in rates of beta-blocker use between 1994 and 1997 among elderly survivors of acute myocardial infarction. Am Heart J. 2000;140:663-671.
19. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20:764-771.
20. Ryan AA. Medication compliance and older people: a review of literature. Int J Nursing Stud. 1999;36:153-162.
21. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24:464-474. (Pubitemid 36286188)
22. Lechat P, Escolano P, Golmard JL, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation. 1997;96:2197- 2205.
23. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
24. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658. (Pubitemid 32479962)
25. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103:1428-1433.
26. Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and betablocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005;26:2259-2268.
27. Gullestad L, Wikstrand J, Deedwania P, et al. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol. 2005;45:252-259.
28. Stone PH, Gibson RS, Glasser SP, et al. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group. Circulation. 1990;82:1962-1972.
29. Andrews TC, Fenton T, Toyosaki N. Subsets of ambulatory myocardial ischemia based on heart rate activity: Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation.1993;88:92-100.
30. Botha P, Parry G, Dark JH, Macgowan GA. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. J Heart Lung Transplant. 2009;28:676-682.
31. Tanaka N, Nozawa T, Yasumura Y, Futaki F, Hiramori K, Suga H. Heart-rate-proportional oxygen consumption for constant cardiac work in dog heart. Jpn J Physiol. 1990;40:503-521.
32. Sambuceti G, Marzilli M, Marraccini P, et al. Coronary vasoconstriction during myocardial ischemia induced by rises in metabolic demand in patients with coronary artery disease. Circulation. 1997;95:2652-2659.
33. Reynolds R, Calzadilla SV, Lee RV. Spontaneous heart rate, propranolol, and ischaemia-induced ventricular fibrillation in the dog. Cardiovasc Res. 1978;12:653-658.
34. Panza JA, Diodati JG, Callahan TS, Epstein SE, Quyyumi AA. Role of increases in heart rate in determining the occurrence and frequency of myocardial ischemia during daily life in patients with coronary artery disease. J Am Coll Cardiol. 1992;20:1092-1098.
35. Pratt CM, McMahon CP, Goldstein S, et al. Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the Asymptomatic Cardiac Ischemia Pilot [ACIP] study). Am J Cardiol. 1996;77:1302-1309 .
36. Chapter 31: Treatment of myocardial ischemia. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11e. Brunton LL, editor-inchief. Lazo JS and Parker KL, associate editors. The McGraw-Hill Companies, Inc.; 2006.
37. Rochon PA, Anderson GA, Tu JV, et al. Use of beta-blocker therapy in older patients after acute myocardial infarction in Ontario. Can Med Assoc J. 1999;161:1403-1408.
38. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;45:438-444.
39. Gislason GH. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27:1153-1158.
40. Fox K, Garcia MA, Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341-1381. (Pubitemid 43998110)
41. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ. The Total Ischaemic Burden European trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J. 1996;17:96-103. (Pubitemid 26111912)
42. Klein WW, Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis. Coron Artery Dis. 2002;13:427-436.
43. van der Vring JA, Daniels MC, Holwerda NJ, et al. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Br J Clin Pharmacol. 1999;47:493-498.
44. Knight CJ, Fox KM. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators. Am J Cardiol. 1998;81:133- 136.
45. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent S16257 on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol. 1996;118:1051-1057.
46. Borer JS. Drug insight: If inhibitors as specific heartrate-reducing agents. Nat Clin Pract Cardiovasc Med. 2004;1:103-109.
47. DiFrancesco D. Characterization of single pacemaker channels in cardiac sino-atrial node cells. Nature. 1986;324:470-173.
48. DiFrancesco D. The contribution of the 'pacemaker' current (If) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol (Lond). 1991;434:23-40.
49. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64:1757- 1765.
50. Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine a novel I(f) inhibitor lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100:149- 155.
51. Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A. Coronary and hemodynamic effects of S16257 a new bradycardic agent in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659-666.
52. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817-823.
53. de Silva R, Fox KM. Angina: ivabradine for treatment of stable angina pectoris. Nat Rev Cardiol. 2009;6:329-330.
54. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529-2536.
55. Tardif JC, Ponikowski P, Kahan T. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebocontrolled trial. Eur Heart J. 2009;30:540-548.
56. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev. 2005;(4):CD003614.